Acorah Software Products - Accounts Production 19.2.350 false true true 31 October 2024 1 November 2023 false 1 November 2024 31 December 2025 31 December 2025 SC454814 Mr Graeme Duncan Dr Ronald Lindsay Mr Fraser Lusty MFMAC SECRETARIES LIMITED iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure SC454814 2024-10-31 SC454814 2025-12-31 SC454814 2024-11-01 2025-12-31 SC454814 frs-core:CurrentFinancialInstruments 2025-12-31 SC454814 frs-core:Non-currentFinancialInstruments 2025-12-31 SC454814 frs-core:ComputerEquipment 2025-12-31 SC454814 frs-core:ComputerEquipment 2024-11-01 2025-12-31 SC454814 frs-core:ComputerEquipment 2024-10-31 SC454814 frs-core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-11-01 2025-12-31 SC454814 frs-core:OtherResidualIntangibleAssets 2025-12-31 SC454814 frs-core:OtherResidualIntangibleAssets 2024-11-01 2025-12-31 SC454814 frs-core:OtherResidualIntangibleAssets 2024-10-31 SC454814 frs-core:OtherReservesSubtotal 2025-12-31 SC454814 frs-core:SharePremium 2025-12-31 SC454814 frs-core:ShareCapital 2025-12-31 SC454814 frs-core:RetainedEarningsAccumulatedLosses 2025-12-31 SC454814 frs-bus:PrivateLimitedCompanyLtd 2024-11-01 2025-12-31 SC454814 frs-bus:FilletedAccounts 2024-11-01 2025-12-31 SC454814 frs-bus:SmallEntities 2024-11-01 2025-12-31 SC454814 frs-bus:AuditExempt-NoAccountantsReport 2024-11-01 2025-12-31 SC454814 frs-bus:SmallCompaniesRegimeForAccounts 2024-11-01 2025-12-31 SC454814 frs-core:CostValuation 2024-10-31 SC454814 frs-core:AdditionsToInvestments 2025-12-31 SC454814 frs-core:CostValuation 2025-12-31 SC454814 frs-core:ProvisionsForImpairmentInvestments 2024-10-31 SC454814 frs-core:ProvisionsForImpairmentInvestments 2025-12-31 SC454814 frs-bus:Director1 2024-11-01 2025-12-31 SC454814 frs-bus:Director2 2024-11-01 2025-12-31 SC454814 frs-bus:Director3 2024-11-01 2025-12-31 SC454814 frs-bus:CompanySecretary1 2024-11-01 2025-12-31 SC454814 frs-core:CurrentFinancialInstruments 1 2025-12-31 SC454814 frs-countries:Scotland 2024-11-01 2025-12-31 SC454814 2023-10-31 SC454814 2024-10-31 SC454814 2023-11-01 2024-10-31 SC454814 frs-core:CurrentFinancialInstruments 2024-10-31 SC454814 frs-core:Non-currentFinancialInstruments 2024-10-31 SC454814 frs-core:OtherReservesSubtotal 2024-10-31 SC454814 frs-core:SharePremium 2024-10-31 SC454814 frs-core:ShareCapital 2024-10-31 SC454814 frs-core:RetainedEarningsAccumulatedLosses 2024-10-31 SC454814 frs-core:CurrentFinancialInstruments 1 2024-10-31
Registered number: SC454814
NEUROCENTRX PHARMA LIMITED
Unaudited Financial Statements
For the Period 1 November 2024 to 31 December 2025
NEUROCENTRX PHARMA LIMITED
Contents
Contents

| Page
--- | ---
Balance Sheet | 1—2
Notes to the Financial Statements | 3—5

Page 1
NEUROCENTRX PHARMA LIMITED
Balance Sheet
As At 31 December 2025
Balance Sheet
Registered number: SC454814

| 31 December 2025 | 31 October 2024
--- | --- | ---
| Notes | £ | £ | £ | £
FIXED ASSETS
Intangible Assets | 4 |  | 14,497 |  | 17,996
Tangible Assets | 5 |  | 752 |  | 2,410
Investments | 6 |  | 600,048 |  | -
|  |  | 615,297 |  | 20,406
CURRENT ASSETS
Debtors | 7 | 19,416 |  | 48,171 |
Cash at bank and in hand |  | 385 |  | 34,430 |
|  | 19,801 |  | 82,601 |
Creditors: Amounts Falling Due Within One Year | 8 | (755,379 ) |  | (620,247 ) |
NET CURRENT ASSETS (LIABILITIES) |  |  | (735,578 ) |  | (537,646 )
TOTAL ASSETS LESS CURRENT LIABILITIES |  |  | (120,281 ) |  | (517,240 )
Creditors: Amounts Falling Due After More Than One Year | 9 |  | (1,643,256 ) |  | (233,000 )
NET LIABILITIES |  |  | (1,763,537 ) |  | (750,240 )
CAPITAL AND RESERVES
Called up share capital | 10 |  | 80 |  | 77
Share premium account |  |  | 3,579,727 |  | 3,540,276
Other reserves |  |  | 32,676 |  | -
Profit and Loss Account |  |  | (5,376,020 ) |  | (4,290,593 )
SHAREHOLDERS' FUNDS |  |  | (1,763,537) |  | (750,240)

Page 1
Page 2
NEUROCENTRX PHARMA LIMITED
Balance Sheet (continued)
As At 31 December 2025
For the period ending 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board

Mr Graeme Duncan Director
29/07/2026

The notes on pages 3 to 5 form part of these financial statements.
Page 2
Page 3
NEUROCENTRX PHARMA LIMITED
Notes to the Financial Statements
For the Period 1 November 2024 to 31 December 2025
Notes to the Financial Statements
1. General Information
NEUROCENTRX PHARMA LIMITED is a private company, limited by shares, incorporated in Scotland, registered number SC454814 . The registered office is Level 5, 9 Haymarket Square, Edinburgh, EH3 8RY.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Going Concern Disclosure
The Company is reliant on raising further funding in order to continue trading. A fund raising process is currently ongoing and the directors are of the opinion that it is appropriate to continue to prepare the accounts on a Going Concern basis.
2.3. Intangible Fixed Assets and Amortisation - Other Intangible
Other intangible asset is a IP License. It is amortised to profit and loss account over its estimated economic life of 15 years.
2.4. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Computer Equipment | 33% straight line

2.5. Foreign Currencies
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
3. Average Number of Employees
Average number of employees, including directors, during the period was: 1 (2024: 1)
1 1
4. Intangible Assets

| Other
--- | ---
| £
Cost
As at 1 November 2024 | 89,981
Disposals | (44,990 )
As at 31 December 2025 | 44,991
Amortisation
As at 1 November 2024 | 71,985
Provided during the period | 3,499
Disposals | (44,990 )
As at 31 December 2025 | 30,494
Net Book Value
As at 31 December 2025 | 14,497
As at 1 November 2024 | 17,996

Page 3
Page 4
NEUROCENTRX PHARMA LIMITED
Notes to the Financial Statements (continued)
For the Period 1 November 2024 to 31 December 2025
5. Tangible Assets

| Computer Equipment
--- | ---
| £
Cost
As at 1 November 2024 | 11,961
As at 31 December 2025 | 11,961
Depreciation
As at 1 November 2024 | 9,551
Provided during the period | 1,658
As at 31 December 2025 | 11,209
Net Book Value
As at 31 December 2025 | 752
As at 1 November 2024 | 2,410

6. Investments

| Subsidiaries
--- | ---
| £
Cost or Valuation
As at 1 November 2024 | -
Additions | 600,048
As at 31 December 2025 | 600,048
Provision
As at 1 November 2024 | -
As at 31 December 2025 | -
Net Book Value
As at 31 December 2025 | 600,048
As at 1 November 2024 | -

7. Debtors

| 31 December 2025 |  | 31 October 2024
--- | --- | --- | ---
| £ |  | £
Due within one year
Other debtors | 19,416 |  | 48,171

Page 4
Page 5
NEUROCENTRX PHARMA LIMITED
Notes to the Financial Statements (continued)
For the Period 1 November 2024 to 31 December 2025
8. Creditors: Amounts Falling Due Within One Year

| 31 December 2025 |  | 31 October 2024
--- | --- | --- | ---
| £ |  | £
Trade creditors | 272,891 |  | 62,646
Other taxes and social security | 14,779 |  | 3,482
Net wages | 10,271 |  | -
Convertible loans | 233,000 |  | 498,326
Accruals and deferred income | 147,723 |  | 55,793
Directors' loan accounts | 10,596 |  | -
Amounts owed to group undertakings | 66,119 |  | -
| 755,379 |  | 620,247

9. Creditors: Amounts Falling Due After More Than One Year

| 31 December 2025 |  | 31 October 2024
--- | --- | --- | ---
| £ |  | £
Convertible loans >1 year | 1,643,256 |  | 233,000

10. Share Capital

| 31 December 2025 |  | 31 October 2024
--- | --- | --- | ---
| £ |  | £
Allotted, Called up and fully paid | 80 |  | 77

Page 5